HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE
出血引起的免疫反应抑制
基本信息
- 批准号:3295964
- 负责人:
- 金额:$ 27.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1988
- 资助国家:美国
- 起止时间:1988-02-01 至 1995-01-31
- 项目状态:已结题
- 来源:
- 关键词:T lymphocyte antibody formation antibody receptor antiidiotype antibody bacterial antigens bacterial pneumonia bactericidal immunity cellular immunity enzyme biosynthesis growth factor helper T lymphocyte hemorrhage immunoglobulin idiotypes immunosuppression interleukin 2 laboratory mouse laboratory rat mixed tissue /cell culture monoclonal antibody ornithine decarboxylase plasma cells polyamines protein biosynthesis serum suppressor T lymphocyte trauma
项目摘要
A depressed immune response appears to be responsible for the impairment
in host defense following hemorrhage and trauma. We have found a
multitude of functional abnormalities in post-hemorrhage T cells.
Initial studies showed that certain functions of B cells are also
abnormal. A 16000 Dalton polypeptide present in hemorrhagic serum was
isolated, partially sequenced, and found to activate suppressor T cells.
These activated suppressor T cells are responsible for most, if not all,
observed abnormalities. With the long term goal of elucidating the
events that lead to the impairment of host defense following hemorrhage
and trauma and to assess potential clinical usefulness of the suppressor
cell activating factor (SCAF), it is the objective of this proposed
investigation to (1) further characterize hemorrhage-induced alterations
in B cell activities and antibody response; (2) ascertain the mechanisms
of action of SCAF at the subcellular and molecular levels; and (3) test
our hypothesis that post-hemorrhage immunodepression and propensity for
developing infection can be prevented or reversed by parental
administration of anti-SCAF or anti-SCAF-receptor antibodies.
Specifically, we propose to (1) determine effects of hemorrhage on serum
levels of bacterial antigen specific antibodies and the number,
percentages, as well as activities of antigen specific splenic plasma
cells; (2) determine the effects of hemorrhage on antibody response of
pulmonary mucosal plasma cells; (3) assess possible hemorrhage-induced
alteration in the regulation of antibody response by determining
interactions of B cells with helper T cells, suppressor T cells, and the
idiotype network following hemorrhage; (4) prepare synthetic and
recombinant SCAF, anti-SCAF antibodies and anti-SCAF-receptor
antibodies; (5) determine effects of parental administration of anti-
SCAF or anti-SCAF-receptor antibodies on hemorrhage-induced depression
of immune response; (6) assess possible protective effect of anti-SCAF
or anti-SCAF-receptor antibodies against experimental pneumonia in the
mouse; (7) ascertain mechanisms of action of SCAF at the cellular,
subcellular and molecular levels by determining its effects on the
generation and release of mediators, cytoplasmic enzyme activation,
nuclear ornithine decarboxylase induction, and polyamine biosynthesis.
Results generated from these studies should lead to a better
understanding of the impairment of host defense against infections that
occurs following hemorrhage and trauma as well as permit the development
of methodologies, such as the measurement of SCAF blood levels, for
identifying patients with hemorrhagic, traumatic, or thermal injuries
who are at particularly high risk of infections. Experimental validation
of our hypotheses that post-hemorrhage immunodepression and propensity
for developing infections can be prevented and/or reversed by parental
administration of anti-SCAF or anti-SCAF-receptor antibodies should
provide new approaches for clinical management of critically III trauma
patients. Looking beyond the present proposal, the role(s) of SCAF in
regulating normal immune response and in mediating immune depressions in
aging, as well as its potential clinical usefulness in organ
transplantation and in the treatment of auto-immune disease such as
systemic lupus erythematosus (SLE) or type 1 diabetes mellitus are
important areas for future investigation.
免疫反应低下似乎是造成这种损伤的原因
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YI-HAN CHANG其他文献
YI-HAN CHANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YI-HAN CHANG', 18)}}的其他基金
HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE
出血引起的免疫反应抑制
- 批准号:
2179689 - 财政年份:1988
- 资助金额:
$ 27.91万 - 项目类别:
HEMORRHAGE-INDUCED SUPPRESSION OF IMMUNE RESPONSE
出血引起的免疫反应抑制
- 批准号:
3295968 - 财政年份:1988
- 资助金额:
$ 27.91万 - 项目类别:
CELLULAR MECHANISMS OF HEMORRHAGED-INDUCED SUPPRESSION
出血引起的抑制的细胞机制
- 批准号:
3295967 - 财政年份:1988
- 资助金额:
$ 27.91万 - 项目类别:
CELLULAR MECHANISMS OF HEMORRHAGED-INDUCED SUPPRESSION
出血引起的抑制的细胞机制
- 批准号:
3295966 - 财政年份:1988
- 资助金额:
$ 27.91万 - 项目类别:
CELLULAR MECHANISMS OF HEMORRHAGED-INDUCED SUPPRESSION
出血引起的抑制的细胞机制
- 批准号:
3295965 - 财政年份:1988
- 资助金额:
$ 27.91万 - 项目类别:
CELLULAR MECHANISMS OF HEMORRHAGED-INDUCED SUPPRESSION
出血引起的抑制的细胞机制
- 批准号:
3295963 - 财政年份:1988
- 资助金额:
$ 27.91万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 27.91万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 27.91万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 27.91万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 27.91万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 27.91万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 27.91万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 27.91万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 27.91万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 27.91万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 27.91万 - 项目类别:














{{item.name}}会员




